Currently, there are 31.68M common shares owned by the public and among those 23.51M shares have been available to trade.
The company’s stock has a 5-day price change of 8.18% and 16.33% over the past three months. SLNO shares are trading 21.61% year to date (YTD), with the 12-month market performance up to 857.93% higher. It has a 12-month low price of $3.69 and touched a high of $53.82 over the same period. SLNO has an average intraday trading volume of 520.24K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 2.35%, 6.53%, and 14.93% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Soleno Therapeutics Inc (NASDAQ: SLNO) shares accounts for 78.16% of the company’s 31.68M shares outstanding.
It has a market capitalization of $1.90B and a beta (3y monthly) value of -1.45. The earnings-per-share (ttm) stands at -$2.43. Price movements for the stock have been influenced by the stock’s volatility, which stands at 5.91% over the week and 6.46% over the month.
Analysts forecast that Soleno Therapeutics Inc (SLNO) will achieve an EPS of -0.64 for the current quarter, -0.65 for the next quarter and -2.07 for current fiscal year. The lowest estimate earnings-per-share for the quarter is -0.67 while analysts give the company a high EPS estimate of -0.67. Comparatively, EPS for the current quarter was -0.95 a year ago. Earnings per share for the fiscal year are expected to decrease by -2.91%, and 14.94% over the next financial year. EPS should shrink at an annualized rate of 15.00% over the next five years, compared to 24.34% over the past 5-year period.
Looking at the support for the SLNO, a number of firms have released research notes about the stock. Robert W. Baird stated their Outperform rating for the stock in a research note on May 10, 2024, with the firm’s price target at $72. Piper Sandler coverage for the Soleno Therapeutics Inc (SLNO) stock in a research note released on February 05, 2024 offered a Overweight rating with a price target of $93. Stifel was of a view on January 23, 2024 that the stock is Buy, while Guggenheim gave the stock Buy rating on November 21, 2023, issuing a price target of $40. Guggenheim on their part issued Buy rating on September 29, 2020.
